首页> 外文期刊>Clinical and experimental allergy : >Hereditary angio‐oedema: a review with particular reference to pathogenesis and treatment
【24h】

Hereditary angio‐oedema: a review with particular reference to pathogenesis and treatment

机译:遗传性血管性水肿:关于发病机制和治疗的综述

获取原文
获取外文期刊封面目录资料

摘要

SummaryHereditary angio‐oedema (HAE) is a rare disease associated with, and caused by, an inherited deficiency of the inhibitor of the activated first component of complement (C1‐inhibitor). The disease is readily diagnosed in the laboratory by measuring C1‐inhibitor levels.Very uncharacteristically for an inherited deficiency, genetic transmission is as an autosomal dominant. The patients are therefore heterozygotes and their deficiency is incomplete; many having up to 20 of the normal amount of inhibitor.It appears most probable that attacks are precipitated by exhaustion of local inhibitor as a result of its consumption by any of the plasma enzymes (plasmin. kininogenase, P.F./Dil as well as C1)with which the inhibitor can react. Thus, conditions associated with increased generation of any of these enzymes may predispose to relapse in HAE. In the absence of all inhibitor C1 activation proceeds autocatalytically and reacting with its substrates C4 and C2 produces a kinin‐like peptide from C2 which appears to be the main mediator of the disease.Attacks of the disease have been successfully treated by replacement of inhibitor using fresh frozen plasma as source. Effective prophylactic treatment has been obtained with ɛ‐aminocaproic acid and its derivatives. These drugs inhibit the activation of the plasma proteases with which the inhibitor reacts and will thus produce an ‘inhibitor sparing’ effect in addition to themselves inhibiting
机译:摘要遗传性血管性水肿(HAE)是一种罕见疾病,与补体第一组分激活的抑制剂(C1抑制剂)的遗传性缺陷相关,并由其引起。该疾病在实验室中通过测量 C1 抑制剂水平很容易诊断。对于遗传性缺陷来说,非常不寻常的是,遗传是常染色体显性遗传。因此,患者是杂合子,其缺陷不完全;许多具有高达正常量的 20% 的抑制剂。最有可能的是,局部抑制剂被抑制剂可以与之反应的任何血浆酶(纤溶酶激肽原酶、P.F./Dil 以及 C1)消耗后,局部抑制剂耗尽后诱发了攻击。因此,与这些酶中任何一种的产生增加相关的疾病都可能导致 HAE 复发。在不存在所有抑制剂的情况下,C1 活化自催化进行,与其底物 C4 和 C2 反应,从 C2 产生激肽样肽,这似乎是该疾病的主要介质。通过使用新鲜冰冻血浆作为来源的抑制剂替代抑制剂,已成功治疗了该疾病的发作。已获得有效的预防性治疗 ɛ-氨基己酸及其衍生物。这些药物抑制与抑制剂反应的血浆蛋白酶的活化,因此除了自身抑制外,还会产生“抑制剂保留”作用

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号